

# Apixaban (Eliquis) Anticoagulation or Thromboprophylaxis [4056]

Use caution in patients with acute renal failure.

## Medications

### Select condition for which therapy is being initiated (Single Response) (Selection Required)

Non-valvular atrial fibrillation (to prevent stroke and systemic embolism)

Pharmacy consult to monitor apixaban (ELIQUIS) therapy      STAT, Until discontinued, Starting S  
Indications: Atrial Fibrillation

Apixaban for Non-valvular Atrial Fibrillation (Single Response)

Reduced dosing is recommended for patients with any 2 of the following characteristics:

1. Age 80 years or greater
2. Body weight 60 kg or less
3. Serum Creatinine 1.5 mg/dL or greater

Normal dosing      5 mg, oral, 2 times daily  
Indications: Atrial Fibrillation

Reduced dosing      2.5 mg, oral, 2 times daily  
Indications: Atrial Fibrillation

Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)

Pharmacy consult to monitor apixaban (ELIQUIS) therapy      STAT, Until discontinued, Starting S  
Indications: Deep vein thrombosis / Pulmonary embolism

apixaban (ELIQUIS) (Single Response)

Initial treatment

**"Followed by" Linked Panel**

apixaban (ELIQUIS) 10 mg PO (Day 1-7)      10 mg, oral, 2 times daily  
Indications: Deep vein thrombosis / Pulmonary embolism

apixaban (ELIQUIS) 5 mg PO (Day 8+)      5 mg, oral, 2 times daily  
Indications: Deep vein thrombosis / Pulmonary embolism

Continuation of treatment

apixaban (ELIQUIS) tablet      5 mg, oral, 2 times daily  
Indications: Deep vein thrombosis / Pulmonary embolism

Prevention of recurrent DVT or PE following treatment doses for at least 6 months

Pharmacy consult to monitor apixaban (ELIQUIS) therapy      STAT, Until discontinued, Starting S  
Indications: Prevention of recurrent DVT or PE

apixaban (ELIQUIS)

apixaban (ELIQUIS) tablet      2.5 mg, oral, 2 times daily  
Indications: Prevention of recurrent DVT or PE

Post-operative thromboprophylaxis following hip and knee surgery

Pharmacy consult to monitor apixaban (ELIQUIS) therapy      STAT, Until discontinued, Starting S  
Indications: VTE prophylaxis

apixaban (ELIQUIS)

apixaban (ELIQUIS) tablet      2.5 mg, oral, 2 times daily  
Indications: VTE prophylaxis

Other indication

Pharmacy consult to monitor apixaban (ELIQUIS) therapy      STAT, Until discontinued, Starting S  
Indications: Other: Specify  
Specify Other Indication:

apixaban (ELIQUIS)

apixaban (ELIQUIS) tablet      oral, 2 times daily  
Indications: Other: Specify  
Specify Other Indication:

## Labs

### Baseline Labs

Per HM policy, baseline labs are required prior to initiation of therapy if not already available.

<input checked="" type="checkbox"/> CBC with platelet and differential	Once For 1 Occurrences
<input checked="" type="checkbox"/> Prothrombin time with INR	Once For 1 Occurrences
<input checked="" type="checkbox"/> Partial thromboplastin time, activated	Once For 1 Occurrences
<input checked="" type="checkbox"/> Basic metabolic panel	Once For 1 Occurrences

#### Follow-up Labs

<input type="checkbox"/> CBC with platelet and differential	AM draw repeats For 3 Occurrences
<input type="checkbox"/> Creatinine level	AM draw repeats For 3 Occurrences
<input type="checkbox"/> Anti Xa Apixaban	AM draw For 1 Occurrences
<input type="checkbox"/> CBC with platelet and differential	User Schedule, Starting S+1 For 3 Occurrences
<input type="checkbox"/> Creatinine level	User Schedule, Starting S+1
<input type="checkbox"/> Anti Xa Apixaban	Once

## Consults